Biotek-snakken — August 2017
-
Biotekselskab vil have nyrekræftmiddel godkendt i første linje
Mens rivalen BMS for nylig skuffede i et klinisk studie inden for nyrekræft, så håber et amerikansk biotekselskab nu at få godkendt sit middel mod sygdommen til patienter, der ikke tidligere har fået medicinsk behandling.
(medwatch.dk)
-
Nogle der overvejer at tegne lidt nye aktier i Expres2ion emissionen? Har et lille frimærke i selskabet.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind